Lonza, a CDMO partner to the biopharma industry, announced the construction of a new small molecule manufacturing complex at its Visp (CH) site. The new manufacturing complex will occup y an overall footprint of approximately 2000 m2 with six levels of manufacturing space. The complex will offer several opportunities for future expansions supporting the small molecules technologies offering, which include drug substance, particle engineering technologies such as spray drying dispersion, and drug product.
This construction project is supported by a capital contribution and a tailored long-term collaboration with a major biopharmaceutical partner to ensure continuity of supply and flexibility, supporting future demand for their product. The first buildout represents a dedicated manufacturing line for antibody-drug conjugate payload molecules, which is expected to start its first operations in Q3 2023. Upon completion, the manufacturing complex will employ approximately 200 people
Lonza is a leading global provider of integrated healthcare solutions. We focus on enabling treatments that prevent illness, support healthier lifestyles and create a healthy environment. We optimize scientific innovation and manufacturing technology to enable our customers to serve their patients and consumers.